Ipsen

Last updated

Ipsen
Company typePublic
Euronext Paris:  IPN
CAC Mid 60 Component
ISIN FR0010259150
Industry Pharmaceutical
Founded1929
FounderHenri Beaufour
HeadquartersBoulogne-Billancourt, France
Key people
Marc de Garidel (Non-executive Chairman)
David Loew (Chief Executive Officer)
ProductsList of medicines
Revenue€2.87 billion (2021)
€1.01 billion (2021)
610,500,000 euro (2020)  OOjs UI icon edit-ltr-progressive.svg
Number of employees
5,700
Websitewww.ipsen.com

Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on transformative medicines in three therapeutic areas: oncology, rare disease and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales. [1] [2]

Contents

Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in more than 100 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index (2005) [3] ,. [4] The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. [5]

History

In 1929, Dr. Henri Beaufour founded the Beaufour Laboratories in Dreux. The first product marketed was Romarene, a rosemary-based medicine intended for the treatment of digestive disorders, discontinued from the market in 2011.

In the 1950s and 1960s, Laboratoires Beaufour underwent a phase of expansion. In 1954, the group launched betaine citrate, used in the symptomatic treatment of dyspepsia. Henri Beaufour's two sons, Albert and Gérard Beaufour, joined the company. [5] The group opened a factory in Dreux in 1961, [6] and another in L'Isle- sur-la-Sorgue in 1965. A research center opened in Plessis-Robinson the same year.

In the 1970s and 1980s, Laboratoires Beaufour created a subsidiary, Ipsen (1975), and began to internationalize its activities. In 1976, the company opened a research center in Milford (Massachusetts) in the U.S. In 1977, the group launched Smecta (diosmectite clay, a gastrointestinal bandage and anti-diarrhoeal agent). [6]

In 1983, the group created the Fondation Ipsen under the aegis of the Fondation de France, to encourage exchanges between scientists in the field of life sciences. [7]

In 1986, the group launched Decapeptyl, [6] used to treat certain pathologies influenced by sex hormones, such as prostate cancer, endometriosis, uterine fibroids and early puberty.

In the 1990s, the group diversified its activity and continued its international expansion. In 1990, an industrial center was created in Signes, in the Var department. In 1992, the group opened a subsidiary in China. In 1994, the group launched Dysport (type A botulinum toxin for the treatment of muscle spasms) after acquiring the British company Speywood (then called Porton International). [8] The same year, the group opened a subsidiary in Russia.

In 1995, the group launched Somatuline, [6] used to treat hypersecretion of growth hormones (acromegaly) and in neuro-endocrine tumors, and in 1996, Forlax [6] was launched.

In 2000, after the death of Albert Beaufour, the company was taken over by his children, Anne Beaufour and Henri Beaufour.

In 2003, the company changed its name to Ipsen [9] and in 2005, it was listed on the Paris Stock Exchange [10] on Euronext. In 2004, the company inaugurated a new botulinum toxin production unit in Wrexham (UK). In 2007, the company established a partnership with Galderma for botulinum toxin type A products in aesthetic medicine. In addition, somatuline was granted marketing authorization in the United States for the treatment of acromegaly.

In 2007, Ipsen shares were included in the SBF 120 stock market index.

In 2007, Dysport was granted marketing authorization in the United States for certain indications in therapeutic and aesthetic medicine. Decapeptyl 6-month formulation receives marketing authorization in 9 European countries from the European Medicines Agency.

In 2011, Ipsen announced a new strategy focusing on several areas, including a refocus on specialty medicine, research and development and international development. [3] In 2013, Ipsen acquired the British company Syntaxin, a leader in the engineering of recombinant botulinum toxin11. In 2014, the company participated in the creation of a joint laboratory with the CNRS - Archi-Pex -, the Commissariat à l'énergie atomique et aux énergies alternatives and the University of Rennes1, with the aim of designing and developing hormone peptides.

In 2015, Ipsen inaugurated a research and development center in Cambridge, Massachusetts. [11]

In 2016, Dysport Injection was approved in the United States for the treatment of lower limb spasticity in children aged two years and older. [12]

In 2016, Ipsen licensed cabozantinib from Exelixis, which received marketing authorization the same year for the second-line treatment of advanced renal cell carcinoma. In January 2017, Ipsen announced the acquisition of certain assets of Merrimack Pharmaceuticals, including Onivyde, for the treatment of pancreatic and ovarian cancer. [13]

In 2019, Ipsen acquired Montreal-based Clementia Pharmaceuticals, specializing in rare bone diseases, [14] , [15] ,. [16] Clementia brought a drug candidate, palovarotene, to Ipsen for a rare genetic disease, fibrodysplasia ossificans progressiva (FOP).

In February 2022, Ipsen announced the proposed sale of the Consumer HealthCare (CHC) division after entering into exclusive negotiations with the French laboratory Mayoly Spindler. [17]  In July 2022, Ipsen completed the divestment of the CHC business to Mayoly Spindler.

In August 2022, Ipsen successfully completed the acquisition of Epizyme and its lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor for adults with relapsed or refractory follicular lymphoma (FL), which was granted Accelerated Approval by the U.S. Food and Drug Administration (FDA) in 2020. As part of the transaction, Ipsen also acquired Epizyme's first-in-class, oral SETD2 inhibitor development candidate.

In January 2023, Ipsen announced it would acquire rare disease specialist Albireo for $952m, bringing into its portfolio Bylvay (odevixibat), a non-systemic ileal bile acid transport inhibitor for the treatment of paediatric patients with pruritus in progressive familial intrahepatic cholestasis (PFIC). [18] [19]

Financial Data

Financial data in EUR millions
Year20172018201920202021
Total sales1,908.72,224.82,576.22,591.62,868.9
Change vs prior year - at actual exchange rates21.1%16.6%15,8%3.5%10.7%
Core operating margin20.8%29.7%30,4%32,0%35.2%
Employees5,4005,7005,8005,7005,700

Shareholding

Ownership of Ipsen's share capital (% of total capital) as of 31 December 2021:

Name% of total capital
Free float40.47%
Beach Tree26.03%
Highrock26.03%
MR Schwabe4.34%
Treasury shares1.57%
Finvestan0.22%
Other registered shareholders0.84%
Employee0.33%
Directors (others)0.17%

Medicines

In Oncology

Cabometyx [20] (cabozantinib) is a tyrosine kinase inhibitor (TKI) used in the treatment of advanced kidney cancer (renal cell carcinoma), liver cancer (hepatocellular carcinoma) in adults previously treated with the medicine sorafenib, as well as in radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) after prior systemic therapy

Decapeptyl [20] (triptorelin) is an analogue of the natural gonadotropin-releasing hormone (GnRH), approved for the treatment of locally advanced metastatic prostate cancer, central precocious puberty (CPP) endometriosis, uterine fibroma, and in-vitro fertilization, and used as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor for women at high-risk of breast cancer recurrence.

Somatuline [20] (lanreotide) is a synthetic (analogue) version of the natural hormone somatostatin, which is found naturally in the human body. Used for the treatment of neuroendocrine tumors (NETs), carcinoid syndrome or acromegaly.

Onivyde [20] (irinotecan liposome injection) is prescribed in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Tazverik (tazemetostat) is a methyl transferase inhibitor of EZH2 (enhancer of zeste homologue 2) used to treat people living follicular lymphoma, which is a cancer of the lymphatic system, as well as epithelioid sarcoma which is a rare, slow-growing type of soft tissue cancer which often begin in the soft tissue under the skin of a finger, hand, forearm, lower leg or foot, and in the abdomen or pelvic area.

These indications are approved under FDA accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

In Rare Disease

Increlex [20] (mecasermin) injection is a prescription medicine used to treat children who are very short for their age because their bodies do not make enough IGF-1. This condition is called primary IGF-1 deficiency.

Sohonos [21] (palovarotene) is an oral investigational, selective retinoic-acid receptor gamma (RARγ) agonist being developed as a potential treatment for people living with the debilitating ultra-rare genetic disorder fibrodysplasia ossificans progressiva (FOP).

In Neuroscience

Dysport [20] (Botulinum toxin) is a prescription medicine used for pathologies characterized by involuntary and uncomfortable muscle contractions (dystonias: blepharospasm, spasmodic torticollis, hemifacial spasm; spasticity: spasticity of the upper or lower limb, dynamic deformation of the equine foot). This drug is also used in aesthetic medicine to temporarily reduce certain wrinkles.

Fondation Ipsen

The Fondation Ipsen pour la recherche thérapeutique, created in 1983 under the aegis of the Fondation de France, supports work in the field of therapeutic research32. In particular is focused on helping improve the lives of patients with rare diseases. [7]

It has contributed to numerous major advances in biological and medical research, organized scientific conferences, and produced literature and content to help patients and the wider community understand rare diseases.

Since 2007, Fondation Ipsen has initiated several series of meetings in partnership with the Salk Institute, the Karolinska Institutet, the Massachusetts General Hospital, the DMMGF (Days of Molecular Medicine Global Foundation), as well as with the journals Nature, Cell and Science. The Fondation Ipsen has published more than 100 books and awarded more than 250 prizes and grants.

In 2021, Fondation Ipsen worked directly with 146 organizations to assess the needs of patients with rare diseases. Fondation Ipsen and Science Magazine organized 9 webinars with the world's leading specialists in rare diseases, as well as policymakers from all over the world.The webinars addressed a variety of essential topics for patients living with rare diseases and their families. The webinars received such a strong response that Science Magazine and the Fondation now co-publish an international magazine for the rare disease community: The Rare Disease Gazette.

Related Research Articles

<span class="mw-page-title-main">Botulism</span> Human and animal disease

Botulism is a rare and potentially fatal illness caused by a toxin produced by the bacterium Clostridium botulinum. The disease begins with weakness, blurred vision, feeling tired, and trouble speaking. This may then be followed by weakness of the arms, chest muscles, and legs. Vomiting, swelling of the abdomen, and diarrhea may also occur. The disease does not usually affect consciousness or cause a fever.

<span class="mw-page-title-main">Botulinum toxin</span> Neurotoxic protein produced by Clostridium botulinum

Botulinum toxin, or botulinum neurotoxin, is a highly potent neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes.

<i>Clostridium botulinum</i> Species of endospore forming bacterium

Clostridium botulinum is a gram-positive, rod-shaped, anaerobic, spore-forming, motile bacterium with the ability to produce the neurotoxin botulinum.

<span class="mw-page-title-main">Gigantism</span> Human growth disorder

Gigantism, also known as giantism, is a condition characterized by excessive growth and height significantly above average. In humans, this condition is caused by over-production of growth hormone in childhood.

<span class="mw-page-title-main">Insulin-like growth factor 1</span> Protein-coding gene in the species Homo sapiens

Insulin-like growth factor 1 (IGF-1), also called somatomedin C, is a hormone similar in molecular structure to insulin which plays an important role in childhood growth, and has anabolic effects in adults.

<span class="mw-page-title-main">Pituitary adenoma</span> Human disease

Pituitary adenomas are tumors that occur in the pituitary gland. Most pituitary tumors are benign, approximately 35% are invasive and just 0.1% to 0.2% are carcinomas. Pituitary adenomas represent from 10% to 25% of all intracranial neoplasms and the estimated prevalence rate in the general population is approximately 17%.

<span class="mw-page-title-main">Octreotide</span> Octapeptide that mimics natural somatostatin pharmacologically

Octreotide, sold under the brand name Sandostatin among others, is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. It was first synthesized in 1979 by the chemist Wilfried Bauer, and binds predominantly to the somatostatin receptors SSTR2 and SSTR5.

<span class="mw-page-title-main">Multiple endocrine neoplasia type 1</span> Medical condition

Multiple endocrine neoplasia type 1 (MEN-1) is one of a group of disorders, the multiple endocrine neoplasias, that affect the endocrine system through development of neoplastic lesions in pituitary, parathyroid gland and pancreas. Individuals suffering from this disorder are prone to developing multiple endocrine and nonendocrine tumors. It was first described by Paul Wermer in 1954.

<span class="mw-page-title-main">Blepharospasm</span> Abnormal contraction or twitch of the eyelid

Blepharospasm is any abnormal contraction of the orbicularis oculi muscle. The condition should be distinguished from the more common, and milder, involuntary quivering of an eyelid, known as myokymia, or fasciculation. In most cases, blepharospasm symptoms last for a few days and then disappear without treatment, but in some cases the twitching is chronic and persistent, causing life-long challenges. In these cases, the symptoms are often severe enough to result in functional blindness. The person's eyelids feel like they are clamping shut and will not open without great effort. People have normal eyes, but for periods of time are effectively blind due to their inability to open their eyelids. In contrast, the reflex blepharospasm is due to any pain in and around the eye.

Galderma S.A. is an American-Swiss pharmaceutical company specializing in dermatological treatments and skin care products. Formerly a subsidiary of L'Oréal and Nestlé, it has been held by a consortium of private institutional investors since 2019.

<span class="mw-page-title-main">Hyperpituitarism</span> Medical condition

Hyperpituitarism is a condition due to the primary hypersecretion of pituitary hormones; it typically results from a pituitary adenoma. In children with hyperpituitarism, disruption of growth regulation is rare, either because of hormone hypersecretion or because of manifestations caused by local compression of the adenoma.

<span class="mw-page-title-main">Diffuse esophageal spasm</span> Medical condition

Diffuse esophageal spasm (DES), also known as distal esophageal spasm, is a condition characterized by uncoordinated contractions of the esophagus, which may cause difficulty swallowing (dysphagia) or regurgitation. In some cases, it may cause symptoms such as chest pain, similar to heart disease. In many cases, the cause of DES remains unknown.

<span class="mw-page-title-main">Laron syndrome</span> Medical condition

Laron syndrome (LS), also known as growth hormone insensitivity or growth hormone receptor deficiency (GHRD), is an autosomal recessive disorder characterized by a lack of insulin-like growth factor 1 production in response to growth hormone. It is usually caused by inherited growth hormone receptor (GHR) mutations.

<span class="mw-page-title-main">Lanreotide</span> Pharmaceutical drug

Lanreotide, sold under the brand name Somatuline among others, is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide.

Pegvisomant, sold under the brand name Somavert, is a growth hormone receptor antagonist used in the treatment of acromegaly. It is primarily used if the pituitary gland tumor causing the acromegaly cannot be controlled with surgery or radiation, and the use of somatostatin analogues is unsuccessful, but is also effective as a monotherapy. It is delivered as a powder that is mixed with water and injected under the skin.

<span class="mw-page-title-main">Acromegaly</span> Human disease that results in excess growth of certain parts of the body

Acromegaly is a disorder that results in excess growth of certain parts of the human body. It is caused by excess growth hormone (GH) after the growth plates have closed. The initial symptom is typically enlargement of the hands and feet. There may also be an enlargement of the forehead, jaw, and nose. Other symptoms may include joint pain, thicker skin, deepening of the voice, headaches, and problems with vision. Complications of the disease may include type 2 diabetes, sleep apnea, and high blood pressure.

<span class="mw-page-title-main">Palovarotene</span> Chemical compound

Palovarotene, sold under the brand name Sohonos, is a medication used for the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. It is a highly selective retinoic acid receptor gamma (RARγ) agonist. It is taken by mouth.

<span class="mw-page-title-main">Irosustat</span> Chemical compound

Irosustat is an orally active, irreversible, nonsteroidal inhibitor of steroid sulfatase (STS) and member of the aryl sulfamate ester class of drugs that was under development by Sterix Ltd and Ipsen for the treatment of hormone-sensitive cancers such as breast cancer, prostate cancer, and endometrial cancer but has not yet been marketed. The drug was first designed and synthesized in the group of Professor Barry V L Potter at the Department of Pharmacy & Pharmacology, University of Bath, working together with Professor Michael J. Reed at Imperial College, London and its initial development was undertaken through the university spin-out company Sterix Ltd and overseen by Cancer Research UK (CRUK). Results of the "first-in-class" clinical trial in breast cancer of an STS inhibitor in humans were published in 2006 and dose optimisation studies and further clinical data have been reported.

Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

<span class="mw-page-title-main">Barry V. L. Potter</span> British biochemist

Barry Victor Lloyd Potter MAE FMedSci is a British chemist, who is Professor of Medicinal & Biological Chemistry at the University of Oxford, Wellcome Trust Senior Investigator and a Fellow of University College, Oxford.

References

  1. "Ipsen: A dynamic, fast-growing specialty care powerhouse".
  2. "Ipsen | Evaluate".
  3. 1 2 "Ipsen réussit son virage vers la cancérologie". Les Echos (in French). 11 September 2017. Retrieved 13 December 2022.
  4. "Ipsen, le défi américain". Les Echos (in French). 1 October 2015. Retrieved 13 December 2022.
  5. 1 2 France, Centre (17 February 2015). "Ipsen a engagé plus de 40 millions d'euros d'investissement entre 2012 et 2016". www.lechorepublicain.fr. Retrieved 13 December 2022.
  6. 1 2 3 4 5 Mariette Finet & Elisabeth Hennebert (2021). From Beaufour to Ipsen. Qualibris Edition.
  7. 1 2 "Rare Disease Foundation - Homepage". Fondation Ipsen. Retrieved 13 December 2022.
  8. Nouvelle, L'Usine (10 November 1994). "PharmacieBeaufour-Ipsen s'installe outre-Manche avec PortonConnu pour sa recherche, Porton International va ouvrir au septième groupe pharmaceutique français les marchés britannique et américain. Le ticket d'entrée: 550millions de francs" (in French).{{cite journal}}: Cite journal requires |journal= (help)
  9. Nouvelle, L'Usine (29 May 2003). "Ipsen succède à Beaufour Ipsen" (in French).{{cite journal}}: Cite journal requires |journal= (help)
  10. "IPSEN € 100.40 | Euronext exchange Live quotes". live.euronext.com. Retrieved 13 December 2022.
  11. "Aux États-Unis, Ipsen transfère ses activités de R&D à Cambridge, Massachusetts, en 2014". www.businesswire.com. 26 September 2013. Retrieved 13 December 2022.
  12. "Ipsen réussit son virage vers la cancérologie". Les Echos (in French). 11 September 2017. Retrieved 9 November 2023.
  13. "France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 billion deal". Reuters. 8 January 2017. Retrieved 9 November 2023.
  14. "Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion". Reuters. 25 February 2019. Retrieved 13 December 2022.
  15. Bourse, Zone (18 April 2019). "Ipsen boucle son acquisition record du canadien Clementia | Zonebourse". www.zonebourse.com (in French). Retrieved 13 December 2022.
  16. Nouvelle, L'Usine (18 April 2019). "Avec l'acquisition de Clementia, Ipsen se renforce dans les maladies rares" (in French).{{cite journal}}: Cite journal requires |journal= (help)
  17. "Ipsen relève ses objectifs pour 2024 et négocie la vente de son pôle santé familiale". Investir (in French). 11 February 2022. Retrieved 13 December 2022.
  18. Dunleavy, Kevin (9 January 2023). "JPM23: Ipsen scoops up liver disease specialist Albireo for $952M". Fierce Pharma. Retrieved 31 January 2023.
  19. "Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases". Ipsen. Retrieved 31 January 2023.
  20. 1 2 3 4 5 6 "Our Products". Ipsen. Retrieved 13 December 2022.
  21. "Research and Development". Ipsen. Retrieved 13 December 2022.